title: Future European health care: cost containment, health care reform and scientific progress in drug research.
abstract: The cost of the development of a new pharmaceutical product from its conception and synthesis through to the regulatory approval process has more than quadrupled in the last 20 years. Both clinical and total development times have increased substantially. To amortize the costs incurred, the pharmaceutical industry has taken an international dimension. The incentives for pharmaceutical firms to discover and develop new drugs depend on the length of the development and regulatory review process plus the potential market size. Recent regulatory, economic and political changes may have significant implications for the future of new drug developments in Europe. The European Union industrial policy felt that there is a need for convergence in the area of pricing. It is recommended that the policy should aim to contain growth in pharmaceutical expenses by means specific to reimbursement rather than direct price controls. By encouraging doctors to prescribe and customers to use generics, competition is enhanced to bring down drug prices. More emphasis is being laid by government in educating customers to cost-awareness and cost-benefit ratios with regard to pharmaceuticals. Concerning clinical trials, European harmonization has been achieved by significant developments: the rights and integrity of the trial subjects are protected; the credibility of the data is established; and the ethical, scientific and technical quality of the trials has improved. Future European health care forecasts a whole change in the pharmaceutical business. Important issues in cost and outcome measurement should be carefully planned and considered in drug development. Due to important mergers and acquisitions, the pharmaceutical sector will consist mainly of important multinational corporations. In this way, valuable new products may be brought to the market.
authors.affiliation: Laboratory of Pharmacology, Université Catholique de Louvain, Cliniques Universitaires Saint Luc, Brussels, Belgium.
authors.forename: G
authors.initials: G
authors.lastname: Emilien
mesh_terms: D003363:Cost Control / Q000639:trends; D017047:Cost Sharing; D017277:Drug Approval / Q000191:economics*; D004341:Drug Evaluation; D004345:Drug Industry / Q000191:economics* / Q000639:trends; D005060:Europe; D005062:European Union; D018166:Health Care Reform / Q000639:trends; D007356:Insurance, Pharmaceutical Services / Q000639:trends*; D008389:Marketing of Health Services; D009313:National Health Programs / Q000191:economics